According to a new analysis “CBD can prevent cardiac oxidative damage in many conditions, such as hypertension, diabetes, or even through the cardiotoxic effects induced by chemotherapy”.
This makes CBD “a potential target for future clinical use to minimize the deleterious effects of many pathophysiologies”, states the study which was published in the journal Current Hypertension Reviews and was epublished on the website for the National Institute of Health. The study was conducted by researchers at Centro Universitário de Volta Redonda and niversidade do Estado de Minas Gerais, both in Brazil.
For this review researchers conducted an analysis of dozens of peer-reviewed studies and discussed “the beneficial effects of CBD treatment on different and common conditions of cardiac oxidative stress such as hypertension, diabetes, or even the cardiotoxic effects induced by chemotherapy.” For the selection of studies “a MEDLINE-based search was performed using the following keywords: “Cannabidiol”, “Oxidative stress”, “Heart”, “Antioxidant”, and “Anti-inflammatory”.
The list of articles was subsequently narrowed down to those containing abstracts and articles published in the English language. Information analysis started with the title, followed by the abstract, and then the complete report.
“The endocannabinoid system is an endogenous system considered a unique and widespread homeostatic physiological regulator”, states the study. “It is made up of type 1 (CB1) and type 2 (CB2) cannabinoid receptors. CBD, in turn, has a low affinity for CB1 and CB2 receptors, and regulates the effects arising from THC as a CB1 partial agonist, which are tachycardia, anxiety, and sedation.” Researchers say that it also acts as a CB2 inverse agonist, “resulting in anti-inflammatory effects.”
Furthermore, “its anticonvulsant, neuroprotective, antipsychotic, antiemetic, anxiolytic, anticancer, and antioxidant effects seem to be linked to other discovered receptors such as GRP55, 5TH1a, TRPV I, TRPV II and the regulation of the intracellular concentration of Ca2+.”
“CBD can prevent cardiac oxidative damage in many conditions, such as hypertension, diabetes, or even through the cardiotoxic effects induced by chemotherapy, which makes it a potential target for future clinical use to minimize the deleterious effects of many pathophysiologies”, researchers claim.
The review notes that “Several studies have already demonstrated the ability of CBD to reduce oxidative stress and inflammation in cardiac tissue in a variety of pathophysiological conditions.” This includes studies demonstrating “that the parallel administration of CBD, at a dose of 5 mg/kg, intraperitoneally, was able to prevent cardiotoxicity responses induced by chemotherapy.”
The study concludes:
In summary, from the data presented, it is possible to observe that CBD has several therapeutic properties, with emphasis on its antioxidant and anti-inflammatory effects. Thus, it was possible to demonstrate that the phytocannabinoid in question can prevent cardiac oxidative and inflammatory damages in various conditions, such as hypertension, diabetes, auto-immune disease or even through the cardiotoxic effects induced by chemotherapy. Thus, CBD presents itself as an important target for future clinical applications, with the intention of minimizing cardiac damage induced by various pathophysiologies.
The study’s full text can be found by clicking here.
